Analysis of the COMPERA 2.0 risk assessment tool in the REPLACE study
Purpose: In REPLACE, patients with pulmonary arterial hypertension (PAH) at intermediate risk despite phosphodiesterase-5 inhibitor (PDE5i) treatment achieved clinical...
Comparison between PAH risk assessment methods including PHORA
Background: Risk assessment is crucial to predict survival and then guide therapeutic management for pulmonary arterial hypertension (PAH) patients. Several risk assessment...
Inhaled iloprost improves right ventricular load-independent contractility in pulmonary hypertension
Background: The adaptation of the right ventricular contractility to its afterload (RV–PA coupling), best measured by the ratio of end-systolic elastance (Ees) and arterial...
News & Updates
Εγγραφείτε για να λαμβάνετε στο e-mail σας όλα τα νέα μας και τις ενημερώσεις μας
Μένουμε Μαζί
Μένουμε Ενήμεροι
Γινόμαστε Δυνατότεροι
